IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) shares dropped 5% during mid-day trading on Thursday after JPMorgan Chase & Co. lowered their price target on the stock from $288.00 to $279.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. IQVIA traded as low as $215.00 and last traded at $216.84. Approximately 224,873 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 1,059,862 shares. The stock had previously closed at $228.31.
Other research analysts have also recently issued research reports about the stock. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird increased their price target on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Truist Financial cut their price target on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $267.27.
Check Out Our Latest Stock Analysis on IQV
Insider Activity
Institutional Trading of IQVIA
A number of institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its stake in shares of IQVIA by 4.9% in the third quarter. Nisa Investment Advisors LLC now owns 11,346 shares of the medical research company’s stock worth $2,689,000 after purchasing an additional 530 shares during the period. Concord Wealth Partners bought a new position in IQVIA during the third quarter valued at about $57,000. State of Alaska Department of Revenue increased its stake in IQVIA by 1.1% during the third quarter. State of Alaska Department of Revenue now owns 29,352 shares of the medical research company’s stock valued at $6,955,000 after acquiring an additional 325 shares during the period. Clear Harbor Asset Management LLC increased its stake in IQVIA by 1.3% during the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after acquiring an additional 50 shares during the period. Finally, Smith Salley Wealth Management increased its stake in IQVIA by 3.8% during the third quarter. Smith Salley Wealth Management now owns 10,393 shares of the medical research company’s stock valued at $2,463,000 after acquiring an additional 377 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.
IQVIA Stock Down 7.3 %
The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market capitalization of $38.59 billion, a P/E ratio of 27.49, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The firm has a 50 day moving average of $238.71 and a 200-day moving average of $230.92.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.22 earnings per share. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
- Five stocks we like better than IQVIA
- Stock Average Calculator
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Breakout Stocks: What They Are and How to Identify Them
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.